c-MET (M1250T)

MET · Variant type: point · HGVS: p.M1250T

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Crizotinib	94.3%	5.7%	91.39
2	Tepotinib	93.5%	6.5%	99.75
3	Cabozantinib	92.5%	7.5%	92.73
4	Capmatinib	91.0%	9.0%	99.75
5	Gilteritinib	82.2%	17.8%	88.97
6	Lenvatinib	73.0%	27.0%	97.74
7	Vemurafenib	66.3%	33.7%	96.49
8	Tivozanib	57.9%	42.1%	92.42
9	Pacritinib	53.7%	46.3%	88.64
10	Fostamatinib	50.5%	49.5%	96.74
11	Defactinib	49.3%	50.7%	92.68
12	Axitinib	45.3%	54.7%	93.23
13	Deucravacitinib	43.8%	56.2%	98.99
14	Repotrectinib	35.4%	64.6%	84.21
15	Afatinib	31.5%	68.5%	98.50
16	Ponatinib	27.0%	73.0%	78.23
17	Selpercatinib	26.4%	73.6%	96.72
18	Nintedanib	22.6%	77.4%	90.23
19	Pazopanib	17.7%	82.3%	97.49
20	Neratinib	17.4%	82.6%	93.18
21	Dacomitinib	16.8%	83.2%	97.99
22	Sunitinib	16.4%	83.6%	91.73
23	Dabrafenib	15.4%	84.6%	94.74
24	Bosutinib	15.1%	84.9%	87.22
25	Brigatinib	15.0%	85.0%	82.96

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Crizotinib	94.3%	—	—
Tepotinib	93.5%	—	—
Cabozantinib	92.5%	—	—
Capmatinib	91.0%	—	—
Gilteritinib	82.2%	—	—
Lenvatinib	73.0%	—	—
Vemurafenib	66.3%	—	—
Tivozanib	57.9%	—	—
Pacritinib	53.7%	—	—
Fostamatinib	50.5%	—	—
Defactinib	49.3%	—	—
Axitinib	45.3%	—	—
Deucravacitinib	43.8%	—	—
Repotrectinib	35.4%	—	—
Afatinib	31.5%	—	—
Ponatinib	27.0%	—	—
Selpercatinib	26.4%	—	—
Nintedanib	22.6%	—	—
Pazopanib	17.7%	—	—
Neratinib	17.4%	—	—
Dacomitinib	16.8%	—	—
Sunitinib	16.4%	—	—
Dabrafenib	15.4%	—	—
Bosutinib	15.1%	—	—
Brigatinib	15.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.3ms